Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

SABBY MANAGEMENT, LLC 13F Holdings -- Portfolio & Top Positions (2026-03-31)

SABBY MANAGEMENT, LLC (CIK 1535610) reported $45.1M across 20 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: SPY ($29.1M, 64.50%), ILCG ($7.4M, 16.51%), SPY ($1.8M, 3.94%), GEVO ($1.4M, 3.18%), ABVX ($857,395, 1.90%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1SPYSPDR S&P 500 ETF$29.1M64.50%447Added
2ILCGISHARES TR$7.4M16.51%300Trimmed
3SPYSPDR S&P 500 ETF$1.8M3.94%2,734Added
4GEVOGEVO INC$1.4M3.18%5,252Trimmed
5ABVXABIVAX SA$857,3951.90%77Trimmed
6PRTGALPHATON CAPITAL CORP$654,7851.45%2.1MNew
7BCTXZBRIACELL THERAPEUTICS CORP$392,1450.87%380,686New
8SNESSENESTECH INC$358,3940.80%218,533Added
9DSYWWBIG TREE CLOUD HLDGS LTD$337,1470.75%137,611New
10KMPHZEVRA THERAPEUTICS INC$316,8800.70%340Added
11BCTXZBRIACELL THERAPEUTICS CORP$309,7040.69%73,915New
12TCTOKEN CAT LTD$241,6860.54%23,239New
13SIDUSIDUS SPACE INC$243,3680.54%1,049New
14CPOPPOP CULTURE GROUP CO LTD$201,1290.45%664,449Trimmed
15MBRXMOLECULIN BIOTECH INC$171,7980.38%75,021New
16BDRXBIODEXA PHARMACEUTICALS PLC$159,0920.35%257,472Added
17RKDAARCADIA BIOSCIENCES INC$158,0850.35%114,554New
18TRXTRX GOLD CORP$150,0000.33%100,000New
19INMINMED PHARMACEUTICALS INC$142,0460.32%220,260Added
20SXTCCHINA SXT PHARMACEUTICALS INC$131,3260.29%78,170New
21CANFCAN FITE BIOFARMA LTD$131,9330.29%42,559New
22REVBWREVELATION BIOSCIENCES INC$119,3180.26%99,432New
23FLAG.UCALIDI BIOTHERAPEUTICS INC$103,8550.23%434,903New
24BJDXBLUEJAY DIAGNOSTICS INC$52,8560.12%28,726New
25LYRALYRA THERAPEUTICS INC$51,1030.11%104,059Trimmed

Source: SEC Form 13F filings · as of 2026-03-31